Xeris Biopharma Holdings, Inc.
corporate_fare Company Profile
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for XERS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for XERS spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Xeris 10-Q: Q3 Revenue $107.2M, Net Income $11.3M; Cash $131.1M
- Xeris Beats Q3 Estimates With 6-Cent EPS and 44% Revenue Growth
- Xeris Q3 Revenue Jumps 44% to $107M; 2026 Guidance Raised, 2030 Target Lifted to $1B+
- Xeris Lifts 2026 Revenue Guidance to $395M–$405M After 44% Q3 Growth
- Xeris Swings to $11.3M Third-Quarter Profit
Financial Snapshot
Short Interest & Short Volume
4.34 days to coverFINRA reported short interest of 8,986,870 shares in XERS as of the October 30, 2026 settlement, a 12.0% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 20.4% of XERS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for XERS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-17.
2028 Notes Fully Retired · Dilution Impact
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →